SUISSE MPC 2 study (Stress Urinary Incontinence Study to assess Safety and Efficacy of Muvon’s Muscle Precursor Cell Therapy).
In the SUISSE MPC 2 study (Stress Urinary Incontinence Study to assess Safety and Efficacy of Muvon’s Muscle Precursor Cell Therapy), researchers at the University of Zurich are currently investigating a novel treatment option. This is a so-called “Phase II study”, which is designed to assess the efficacy and safety of the new treatment option.
The treatment option is a cell therapy. Patients are given the body’s own muscle progenitor cells: a new treatment approach that could improve the symptoms of urinary incontinence (Home – SUISSE MPC 2-Studie (muvon-studie.ch)